Plaque Psoriasis Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
| Status | Recruiting |
| Enrollment | 75 |
| Est. completion date | July 2025 |
| Est. primary completion date | April 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Inclusion Criteria: - Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline - Have venous access sufficient to allow for blood sampling - Are able to swallow oral medication - Agree to skin biopsies Exclusion Criteria: - Have any other skin conditions, excluding plaque psoriasis - Have a current or recent acute, active infection - Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus. - Are lactating or breastfeeding women |
| Country | Name | City | State |
|---|---|---|---|
| United States | DermDox Centers for Dermatology | Camp Hill | Pennsylvania |
| United States | Remington Davis Clinical Research | Columbus | Ohio |
| United States | Driven Research | Coral Gables | Florida |
| United States | Psoriasis Treatment Center of Central New Jersey | East Windsor | New Jersey |
| United States | Schweiger Dermatology Group | Hackensack | New Jersey |
| United States | Austin Institute for Clinical Research | Houston | Texas |
| United States | Center for Clinical Studies | Houston | Texas |
| United States | Metropolitan Dermatology - Clark | Kenilworth | New Jersey |
| United States | Dermatology Research Associates | Los Angeles | California |
| United States | Clinical Science Institute | Santa Monica | California |
| United States | Accellacare - Winston-Salem | Winston-Salem | North Carolina |
| United States | Conquest Research | Winter Park | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Eli Lilly and Company |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI 75) | Week 12 | ||
| Secondary | Mean Change from Baseline in Body Surface Area (BSA) | Baseline, Week 12 | ||
| Secondary | Mean Change from Baseline in Dermatology Life Quality Index (DLQI) | Baseline, Week 12 | ||
| Secondary | Pharmacokinetics (PK): Plasma Concentration of LY3972406 | Week 12 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01194219 -
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
| Recruiting |
NCT06030076 -
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
|
||
| Completed |
NCT04263610 -
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
|
Phase 4 | |
| Completed |
NCT02601469 -
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT05600036 -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
| Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT05036889 -
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
|
N/A | |
| Completed |
NCT04603027 -
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT03638258 -
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT02881346 -
Efficacy and Tolerability of Enstilar® in Daily Practice
|
||
| Recruiting |
NCT02611349 -
Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT02251678 -
Evaluate the Effect of Elimune Capsules
|
Phase 1 | |
| Completed |
NCT01987843 -
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
| Terminated |
NCT01708629 -
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
|
Phase 3 | |
| Withdrawn |
NCT00747032 -
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT01230138 -
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
| Suspended |
NCT01228656 -
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
|
Phase 2 | |
| Completed |
NCT00540618 -
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
|
Phase 2 |